BioLineRX
BLRX
18 hedge funds and large institutions have $3.37M invested in BioLineRX in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 11 closing their positions.
0.01% less ownership
Funds ownership: 0.03% → 0.02% (-0.01%)
36% less funds holding
Funds holding: 28 → 18 (-10)
63% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 8
67% less capital invested
Capital invested by funds: $10.3M → $3.37M (-$6.96M)
82% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 11
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$141K |
| 2 |
LPL Financial
San Diego,
California
|
+$52.9K |
| 3 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
+$11.9K |
| 4 |
AWS
Atria Wealth Solutions
New York
|
+$6.93K |
| 5 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
+$3.21K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$2.59M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$953K |
| 3 |
ACM
Altium Capital Management
New York
|
-$778K |
| 4 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$267K |
| 5 |
AWM
Apollon Wealth Management
Mount Pleasant,
South Carolina
|
-$45K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OM
26
Opaleye Management
Boston,
Massachusetts
| – | -$16K | -417 | Closed |
|
|
SSA
27
Schonfeld Strategic Advisors
New York
| – | -$13K | -355 | Closed |
|
28
Millennium Management
New York
| – | -$12K | -335 | Closed |
|
29
Simplex Trading
Chicago,
Illinois
| – | -$59 | -2 | -40% |
|
BLRX Hedge Fund Activity: Q4 2022 in Review
18 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q4 2022, worth a combined $3.37M — down 67% from $10.3M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of BLRX and 2 opened new positions — a net loss of 9 holders — while 8 trimmed existing stakes and 3 added.
The largest buyer was Renaissance Technologies, adding an estimated $141K. The largest seller was Armistice Capital, exiting entirely with an estimated $2.59M sold.
- 18 institutional investors held BioLineRX (BLRX) as of Q4 2022, down from 28 in Q3 2022.
- Funds reported $3.37M of BioLineRX stock for Q4 2022, down 67% quarter-over-quarter.
- 2 funds opened new BioLineRX positions in Q4 2022 and 11 closed out, a net change of -9 holders.
- The largest BioLineRX buyer in Q4 2022 was Renaissance Technologies, an estimated $141K added.
- The largest BioLineRX seller in Q4 2022 was Armistice Capital, an estimated $2.59M sold.
Based on aggregated 13F filings for Q4 2022.